Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NiKang KRAS G12D inhibitor
- Development stage
- Preclinical
- Lead developer
- NiKang Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NiKang KRAS G12D inhibitor is a preclinical small molecule designed to selectively target and inhibit the KRAS G12D oncogenic mutant. KRAS G12D is a frequent driver mutation in several aggressive malignancies, including pancreatic cancer, colorectal cancer, and lung adenocarcinoma. By binding to the G12D mutant form of the KRAS protein, the inhibitor blocks the constitutive activation of downstream signaling pathways, such as MAPK/ERK and PI3K/AKT, which are essential for tumor cell proliferation and survival. Developed by NiKang Therapeutics, this compound aims to provide a targeted therapeutic option for patients with solid tumors harboring this specific genetic alteration.
- Other names
- KRAS G12D inhibitor
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on NiKang KRAS G12D inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NiKang KRAS G12D inhibitor.